Ontogeny of adrenal steroid biosynthesis: Why girls will be girls

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Male and female external genitalia appear identical early in gestation. Testosterone exposure at 8-12 weeks' gestation causes male differentiation. Female fetuses virilize if their adrenals secrete excessive levels of androgens, as occurs in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. This can be ameliorated by administering dexamethasone to the mother. A study by Goto et al. in this issue of the JCI provides a rationale for this treatment by demonstrating that the fetal hypothalamic-pituitary-adrenal axis is fully functional when the genitalia differentiate (see the related article beginning on page 953). Dexamethasone suppresses this axis, reducing abnormal secretion of adrenal androgens. Their results also show that cortisol synthesis by the fetal adrenal decreases after this period, allowing the adrenal to secrete high levels of dehydroepiandrosterone, an androgen precursor. However, this does not virilize female fetuses because androgens are aromatized to estrogens in the placenta. Thus normal sexual differentiation requires exquisite timing of fetal cortisol and androgen secretion versus placental capacity for aromatization.

Original languageEnglish (US)
Pages (from-to)872-874
Number of pages3
JournalJournal of Clinical Investigation
Volume116
Issue number4
DOIs
StatePublished - Apr 1 2006

Fingerprint

Androgens
Steroids
Dexamethasone
Hydrocortisone
Fetus
Female Genitalia
Pregnancy
Sex Differentiation
Genitalia
Dehydroepiandrosterone
Placenta
Testosterone
Estrogens
Mothers
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ontogeny of adrenal steroid biosynthesis : Why girls will be girls. / White, Perrin C.

In: Journal of Clinical Investigation, Vol. 116, No. 4, 01.04.2006, p. 872-874.

Research output: Contribution to journalArticle

@article{277f573fe93c4f2ebaef8fa23db8da4b,
title = "Ontogeny of adrenal steroid biosynthesis: Why girls will be girls",
abstract = "Male and female external genitalia appear identical early in gestation. Testosterone exposure at 8-12 weeks' gestation causes male differentiation. Female fetuses virilize if their adrenals secrete excessive levels of androgens, as occurs in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. This can be ameliorated by administering dexamethasone to the mother. A study by Goto et al. in this issue of the JCI provides a rationale for this treatment by demonstrating that the fetal hypothalamic-pituitary-adrenal axis is fully functional when the genitalia differentiate (see the related article beginning on page 953). Dexamethasone suppresses this axis, reducing abnormal secretion of adrenal androgens. Their results also show that cortisol synthesis by the fetal adrenal decreases after this period, allowing the adrenal to secrete high levels of dehydroepiandrosterone, an androgen precursor. However, this does not virilize female fetuses because androgens are aromatized to estrogens in the placenta. Thus normal sexual differentiation requires exquisite timing of fetal cortisol and androgen secretion versus placental capacity for aromatization.",
author = "White, {Perrin C.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1172/JCI28296",
language = "English (US)",
volume = "116",
pages = "872--874",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Ontogeny of adrenal steroid biosynthesis

T2 - Why girls will be girls

AU - White, Perrin C.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Male and female external genitalia appear identical early in gestation. Testosterone exposure at 8-12 weeks' gestation causes male differentiation. Female fetuses virilize if their adrenals secrete excessive levels of androgens, as occurs in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. This can be ameliorated by administering dexamethasone to the mother. A study by Goto et al. in this issue of the JCI provides a rationale for this treatment by demonstrating that the fetal hypothalamic-pituitary-adrenal axis is fully functional when the genitalia differentiate (see the related article beginning on page 953). Dexamethasone suppresses this axis, reducing abnormal secretion of adrenal androgens. Their results also show that cortisol synthesis by the fetal adrenal decreases after this period, allowing the adrenal to secrete high levels of dehydroepiandrosterone, an androgen precursor. However, this does not virilize female fetuses because androgens are aromatized to estrogens in the placenta. Thus normal sexual differentiation requires exquisite timing of fetal cortisol and androgen secretion versus placental capacity for aromatization.

AB - Male and female external genitalia appear identical early in gestation. Testosterone exposure at 8-12 weeks' gestation causes male differentiation. Female fetuses virilize if their adrenals secrete excessive levels of androgens, as occurs in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. This can be ameliorated by administering dexamethasone to the mother. A study by Goto et al. in this issue of the JCI provides a rationale for this treatment by demonstrating that the fetal hypothalamic-pituitary-adrenal axis is fully functional when the genitalia differentiate (see the related article beginning on page 953). Dexamethasone suppresses this axis, reducing abnormal secretion of adrenal androgens. Their results also show that cortisol synthesis by the fetal adrenal decreases after this period, allowing the adrenal to secrete high levels of dehydroepiandrosterone, an androgen precursor. However, this does not virilize female fetuses because androgens are aromatized to estrogens in the placenta. Thus normal sexual differentiation requires exquisite timing of fetal cortisol and androgen secretion versus placental capacity for aromatization.

UR - http://www.scopus.com/inward/record.url?scp=33645531914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645531914&partnerID=8YFLogxK

U2 - 10.1172/JCI28296

DO - 10.1172/JCI28296

M3 - Article

C2 - 16585958

AN - SCOPUS:33645531914

VL - 116

SP - 872

EP - 874

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -